News Releases

Completion of Phase 1 Study for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 BALANCE Trial of ALPN-101 in Acute GVHD Open for Enrollment NEON-1 Trial of ALPN-202 in Advanced Malignancies Open for Enrollment Orphan Drug Designations by the U.S.

Company to Hold Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 30, 2020 SEATTLE --(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and

SEATTLE --(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40 th Annual Healthcare Conference scheduled for Tuesday, March 3, 2020 at 11:20 am. Eastern Time .

SEATTLE --(BUSINESS WIRE)--Feb. 25, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March.

SEATTLE --(BUSINESS WIRE)--Jan. 24, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead autoimmune/inflammatory

SEATTLE --(BUSINESS WIRE)--Jan. 6, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s &

ALPN-101 demonstrates ability to potently inhibit both T and B cell responses in first-in-human study Human experience supports both IV and SQ dosing regimens SEATTLE --(BUSINESS WIRE)--Dec. 9, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused

SEATTLE --(BUSINESS WIRE)--Nov. 26, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at

Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30 p.m. ET Today SEATTLE --(BUSINESS WIRE)--Nov.

ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Alpine Immune Sciences, Inc.